The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Bayer; Foundation Medicine; Genentech/Roche; Ipsen; Mersana; Tesaro
Research Funding - Aravive (Inst); ArQule (Inst); AstraZeneca (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Roche (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Agenus; Karyopharm Therapeutics; Merck; Roche; Tesaro
 
Minal A. Barve
No Relationships to Disclose
 
James Fredric Strauss
Employment - Dialectic Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Johnson & Johnson; Merck
Consulting or Advisory Role - Tempus
Other Relationship - Dialectic Therapeutics
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Bayer; Exelixis; Incyte
Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst); Tesaro (Inst)
 
Kathleen N. Moore
Honoraria - Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Clovis Oncology; Eisai; Genentech/Roche; Immunogen; Janssen Oncology; Merck; Mersana (Inst); OncoMed; Pfizer/EMD Serono; Samumed; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
 
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule; Bayer
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
Corrine Zarwan
Consulting or Advisory Role - Advance Medical; Advance Medical; Perceptive Informatics; Revere Pharmaceuticals
Research Funding - EMD Serono; Merrimack; Novartis; Tesaro
Travel, Accommodations, Expenses - Pfizer
 
Charles K Anderson
No Relationships to Disclose
 
Joseph Buscema
Employment - Arizona Oncology
Leadership - Arizona Oncology
Stock and Other Ownership Interests - McKesson
Honoraria - Caris Life Sciences
Consulting or Advisory Role - Caris Life Sciences
 
Deborah Blythe Doroshow
Consulting or Advisory Role - Boehringer Ingelheim; Ipsen
Travel, Accommodations, Expenses - Ipsen
 
William Jeffery Edenfield
Consulting or Advisory Role - Chimerix
 
Ursula A. Matulonis
Honoraria - Advaxis
Consulting or Advisory Role - Immunogen; Merck; Novartis
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca
 
Timothy F. Burns
Consulting or Advisory Role - Abbvie/Stemcentrx; Blueprint Medicines; Novartis; Thermo Fisher Scientific
 
Dirk Huebner
Employment - Mersana
Leadership - Mersana
Stock and Other Ownership Interests - Mersana
 
Valerie Malyvanh Jansen
Employment - Lilly; Mersana
Stock and Other Ownership Interests - Lilly; Mersana
 
Rebecca Mosher
Employment - Mersana; Novartis (I)
Stock and Other Ownership Interests - Mersana; Novartis; Novartis (I)
Patents, Royalties, Other Intellectual Property - Mersana; Novartis (I)
 
Donna Jarlenski
Employment - Mersana
Leadership - Mersana
Stock and Other Ownership Interests - Gilead Sciences; Merck; Mersana; Momenta Pharmaceuticals; Vertex
Patents, Royalties, Other Intellectual Property - Mersana
 
Anthony W. Tolcher
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - AbbVie (Inst); AbGenomics International (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Axiom Biotechnologies (Inst); Bayer (Inst); BioInvent (Inst); Boston Biomedical (Inst); Cello Health (Inst); EMD Serono (Inst); Forbius (Inst); Genentech/Roche (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunome (Inst); Immunome (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); OSI Pharmaceuticals (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ridgeway Therapeutics (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Seven and Eight Biopharmaceuticals (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Boehringer Ingelheim (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)